Quantcast
Last updated on April 16, 2014 at 16:51 EDT

Latest Astellas Pharma Inc. Stories

2011-04-11 08:09:00

STAINES, England, April 11, 2011 /PRNewswire/ -- Astellas Pharma Europe Ltd. (APEL), the European subsidiary of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies, today announced the appointment of Ken Jones as its President and CEO. Mr Jones, who since July 2007 has held the position of COO at Astellas Pharma Europe Ltd., succeeds Mr Masao Yoshida, who has been appointed as President and CEO of Astellas Pharma US, Inc., the U.S. subsidiary of...

2011-03-30 15:05:00

SAN MATEO, Calif., March 30, 2011 /PRNewswire/ -- Recent Highlights: Qutenza(®) (capsaicin) 8% patch launch in US by NeurogesX sales force drives early adoption by large US institutions; 238 hospitals purchased as of 4Q10, up 54% from 3Q10 Medicare Part B coverage confirmed Q4 2010 revenue totaled $2.3 million including $0.5 million U.S. Qutenza product revenue EU launch by Astellas advancing, with Qutenza available in 17 countries at December 31, 2010 NGX-1998 Phase 2...

2011-03-24 03:59:00

STAINES, England, March 24, 2011 /PRNewswire/ -- The Astellas European Foundation has today announced financial support to the Japanese Red Cross Society for their work to assist those impacted by the earthquake and tsunami on Friday, 11th March. The Japanese Red Cross Society is working with the local government of the affected region and the support will help provide aid to the local population. Mr. Ken Jones, Chief Operating Officer of Astellas Pharma Europe Ltd. and a Trustee of...

2011-03-22 09:36:00

TOKYO, March 22, 2011 /PRNewswire-FirstCall/ -- Astellas Pharma Inc.(TSE:4503,"Astellas") ( http://www.astellas.com/en/corporate/) today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition[1,2]. These data were presented for the first time this week at...

2011-03-20 19:01:00

VIENNA, March 21, 2011 /PRNewswire/ -- The Astellas European Foundation is delighted to announce the winner of the 2011 Urology Grant: Mr James Catto from the University of Sheffield, UK The University's team led by Mr Catto received the grant of US$ 300,000 to support work on their project entitled 'Examination of the role of non-coding RNA in the mediation of chemoresistance in bladder cancer' at the Astellas European Foundation Award Event, last night. Dr Ayad Abdulahad,...

2011-02-07 07:00:00

SAN DIEGO & STAINES, England, Feb. 7, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) and Astellas Pharma Europe Ltd. ("Astellas") announced today the signing of an exclusive collaboration and license agreement to develop and commercialize fidaxomicin, an investigational antibiotic for CDI, in Europe and certain other countries in the Middle East, Africa and the Commonwealth of Independent States (CIS). (Logo:...

2011-01-10 07:10:00

TOKYO, Jan. 10, 2011 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today that it has engaged Citigroup Global Markets Inc. to conduct, in conjunction with executive management, a review of the Company's strategic alternatives with regard to its Prosidion subsidiary. Prosidion was acquired as part of Astellas' acquisition of OSI Pharmaceuticals in June 2010. Prosidion's assets include two drug candidates in development for diabetes and obesity, as well as a patent estate...

2010-11-29 15:05:00

SAN FRANCISCO and TOKYO, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has...

2010-11-15 05:00:00

PRINCETON, N.J., Nov. 15, 2010 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into a license agreement with Agensys, Inc., an affiliate of Tokyo based Astellas Pharma Inc., providing Agensys with access to BioWa's POTELLIGENT® Technology platform for the purpose of identifying antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC). "We are extremely pleased about our Agreement with Agensys, a leading monoclonal antibody organization...

2010-11-09 15:00:00

MERIDEN, Conn., Nov. 9, 2010 /PRNewswire/ -- Protein Sciences Corporation (PSC) announced that it has expanded its 2006 agreement with UMN Pharma, Inc. (UMN), to which it licensed exclusive rights to commercialize FluBlok® and PanBlok® (together "PSC's influenza vaccines") in the Japan market. The amendment allows UMN to enter into collaboration agreements with Astellas Pharma Inc. (Astellas) and IHI Corporation (IHI). Astellas' role will be to support...